Peginterferon_alfa-2a: profile and news

Human Genome Sciences Presents Interim Results of Phase 2b Trial ...  May 1, 2006
4)). The fourth treatment group serves as the active control group and receives 180-mcg doses of subcutaneously administered peginterferon alfa-2a (Pegasys) at ... - PR Newswire (press release),

Chronic Hepatitis B Patients Still in Remission Two Years After ...  Apr 28, 2006
April 28, 2006 -- In two hepatitis B studies, researchers have confirmed that patients treated for one year with Pegasys(R) (peginterferon alfa-2a (40KD)) have ... - DG News

New PEGASYS(R) Trial Shows Six Months of Treatment is Optimal for ...  May 1, 2006
In the trial, patients were randomised to receive PEGASYS(R) (peginterferon alfa-2a (40KD)) 180 mg once weekly plus COPEGUS(R) (ribavirin) 800 mg daily for ... - PR Newswire UK (press release),

Roche's Innovative Oral Polymerase Inhibitor Shows Strong ...  May 1, 2006
Further trials are planned to study how well R1626 works in combination with Roche's current hepatitis drugs, PEGASYS(r) (peginterferon alfa-2a (40KD)) and ... - PR Newswire UK (press release),

New Oral Polymerase Inhibitor Shows Promising Results in Chronic ...  Apr 29, 2006
Further trials are planned to study how well R1626 works in combination with PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin). ... - Yahoo! News (press release)

ΞΕÎ?Η ΔΗΜΟΣΙΕΥΣΗ-ΑÎ?ΑΚΟΙÎ?ΩΣΗ ΤΥΠΟΥ-PRN ...  Apr 27, 2006
In two hepatitis B studies, researchers have confirmed that patients treated for one year with PEGASYS(R) (peginterferon alfa-2a (40KD)) have a durable ... - Αθηναικο ΠÏ?ακτοÏ?είο Ειδήσεων,

PEGASYS(R) ACCELERATE Trial Shows Six Months of Treatment Is ...  Apr 29, 2006
PRNewswire/ -- Roche announced today that results from a new trial have shown that 24 weeks of therapy with PEGASYS(R) (peginterferon alfa-2a) combined with ... - PR Newswire (press release),

The ticking time bomb of liver disease  May 2, 2006
...good news announced in Vienna is that research has shown that the long-term treatment of genotype 2 and 3 with Pegasys (peginterferon alfa- 2a) and Ribavirin ... - Times Online,

Roche Oral Drug Shows Promise in Hepatitis C  May 5, 2006
Further trials are planned to study how well R1626 works in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). ... - International News Service,

Roche study shows hepatitis C patients need six months of ...  May 3, 2006
Patients were randomized to receive Pegasys (peginterferon alfa-2a) 180mcg once weekly plus Copegys (ribavirin) 800mg daily for either 16 or 24 weeks, followed ... - Pharmaceutical Business Review

COMUNICADO: Pacientes de Hepatitis B crónica permanecen en estado ...  Apr 27, 2006
The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) [PEGASYS(R)] sustain responses 2 years post-treatment ... - Europa Press,

New Data Highlight Anti-HCV Activity of Investigational Oral ...  Apr 26, 2006
...presentation titled "Initial Results of a 14-Day Study of the Hepatitis C Virus Protease Inhibitor VX-950, In Combination with Peginterferon-alfa-2a" will be ... - Yahoo! News (press release)

Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands ...  Apr 23, 2006
COPEGUS tablets are used in combination with PEGASYS(R) (peginterferon alfa-2a (40 KD)), the world's leading treatment for chronic hepatitis C. ... - PR Newswire UK (press release),